Looking to the Future

At Syneos Health, we look toward the future as we apply novel approaches to oncology drug development and innovative trial designs, including cellular and gene therapy clinical trials and investigator-led and cooperative group trials.

To provide unparalleled depth of expertise, our Novel and Emerging Therapies group is further specialized in three areas:

 

 

Our specialist Hematology-Oncology Teams have worked on some of the most promising novel and emerging therapies in development, in indications ranging from non-Hodgkin’s lymphoma and chronic lymphocytic leukemia to acute myeloid leukemia and multiple myeloma, transitioning them from early phase to marketing authorization.

 

For example, in Hematology-Oncology...

We are proud to be providing full-service clinical development support to the Leukemia and Lymphoma Society’s “BeatAML” Master Trial, a ground-breaking targeted therapy umbrella trial designed to expedite development of innovative therapies for acute myeloid leukemia patients.

 

 

In Cell and Gene Therapy...

We understand that these clinical trials often involve treatment aspects that are novel to investigators, site staff and patients alike, involve very complex logistical considerations and are taking place in a rapidly evolving regulatory landscape.

Cell and Gene Therapy at the center

The patient journey through these trials is also uniquely challenging – involving a one-time treatment and long-term follow-up over many years – a period of time that often coincides with changes in patients’ lives that can create significant challenges to patient retention.

Whether motivated by the personal journey of a cancer patient or the challenge and rigor of cancer clinical research, at Syneos Health we are passionate about collaborating for a cure. 

Explore Our Experience:

 

We bring deep experience managing these challenges to each Cell and Gene Therapy (CGT) engagement, supported by the Syneos Health Cell and Gene Therapy Consortium, the hub for our knowledge and experience base in CGT preclinical/clinical development and commercialization.

Cell and Gene Therapy Studies and Patients

;